Tutorial video of the Diabetes Toolbox by the author

2022-11-27

Weight Management


2022-11-21

New Tab

  • Weight Management

Diabetes Canada - New

Renal Function - KERENDIA®


2022-11-19

Renal Function - KERENDIA®

  • Health Canada approves KERENDIA® (finerenone) as an adjunct to standard of care therapy in adults with chronic kidney disease (CKD) and type 2 diabetes (T2D). (monograph coming soon)

2022-11-17

CLASSES - Jardiance®

  • New study - EMPA-Kidney (Jardiance and renal function) was presented to the ASN on November 4th! You will find attached a digital copy of the study published in the NEJM

2022-11-12

Blood Glucose Meters


2022-11-02

Insulin - Trésiba®

  • New monograph with indication in Pregnancy (see point 7.11)

2022-10-28

Diabetes Canada


2022-10-26

CLASSES - Ozempic®


2022-10-05

Continuing Education


2022-08-26

Blood Glucose Monitoring


2022-08-18

Coverage

  • Since August 17, the sensor FreestyleMCLibre 2 is now covered by RAMQ under certain criteria.

2022-08-03

CLASSES

  • Tirzépatide(Mounjaro) approuvé pour le traitement du DB2 par la FDA en mai 2022 au Canada à venir Résultats très impressionnants sur la baisse A1C et le poids. Voir le résumé du programme Surpass
  • Ozempic® - Clinical Trials: SEMA 2.4 (STEP 2) + SUSTAIN FORTE *Semaglutide 2 mg and 2.4 mg are not yet available for purchase in Canada (coming soon)

Glucagon

  • La présente a pour but de vous informer qu’Eli Lilly and Company a décidé de cesser la distribution de GLUCAGON (Glucagon pour injection, source ADNr) pour tous les marchés. Nous avons décidé d’arrêter la fabrication du GLUCAGON (Glucagon pour injection, source ADNr) et de notre trousse d’urgence de GLUCAGON à l’échelle mondiale en raison de la diminution de la demande et de nos efforts pour rationaliser nos processus de fabrication.
    Nous comprenons qu’il est essentiel pour les personnes atteintes de diabète d’avoir un traitement par glucagon d’urgence à portée de main en cas d’hypoglycémie sévère. Notre produit de glucagon en vaporisateur nasal demeurera disponible au Canada pour le traitement de l’hypoglycémie sévère chez les personnes diabétiques traitées à l’insuline (âgées de 4 ans et plus), lorsqu’une altération de la conscience empêche la prise de glucides par voie orale.
    Lilly avise les médecins et les autres fournisseurs de soins de santé des échéanciers de l'arrêt de la distribution, que vous trouverez ci-dessous, afin de leur laisser suffisamment de temps pour discuter d’autres options de traitement par le glucagon avec leurs patients qui utilisent actuellement le GLUCAGON de Lilly (Glucagon pour injection, source ADNr) et de les transférer vers d’autres formes de traitement.
    Nous prévoyons que la dernière distribution de GLUCAGON (Glucagon pour injection, source ADNr) de Lilly aux distributeurs pharmaceutiques au Canada aura lieu vers juillet 2023. Bien qu’il s’agisse de la dernière date de distribution prévue, GLUCAGON peut être utilisé jusqu’à la date d’expiration indiquée sur le produit.

Lifestyle


See more...

Blood Glucose Meters

Product Guide DQ (FR) ACCU-CHEK® Roche - Diabetes Care ACCU-CHEK® Roche - Patient Engagement-Coaching Program Ascencia Contour® - Diabetes Care Tutoriels OneTouch Verio ReflectTM

Codes / Indications RAMQ

EN23

When a sulfonylurea is not tolerated or ineffective.

  • Amaryl®

EN167

For the treatment of people with type 2 diabetes:
- As monotherapy when metformin and a sulfonylurea are contraindicated or not tolerated.

  • Invokana®
  • Januvia®
  • Jardiance®
  • Nesina®
  • Trajenta®

EN148

For the treatment of people with type 2 diabetes:
- In combination with metformin, when a sulfonylurea is contraindicated, not tolerated or ineffective.

  • Invokana®
  • Onglyza®
  • Januvia®
  • Jardiance®
  • Nesina®
  • Forxiga®

EN149

For the treatment of people with type 2 diabetes:
- In combination with a sulfonylurea, when metformin is contraindicated, not tolerated or ineffective.

  • Invokana®
  • Onglyza®
  • Nesina®
  • Forxiga®

EN150

For the treatment of people with type 2 diabetes:
When a sulfonylurea is contraindicated, not tolerated or ineffective; AND
- When the daily doses of metformin have been stable for at least a month.

  • Janumet®
  • Janumet®XR
  • Komboglyze®
  • JentaduetoTM
  • KazanoTM
  • Xigduo®

EN179

For the treatment of type 2 diabetes, in combination with one or more antidiabetic agents, in persons with a history of atherosclerotic heart disease (ASIC) or atherosclerotic vascular disease (ASK) and whose glycated hemoglobin (HbA1c) is ≥ 7%.

The nature of atherosclerotic heart disease (MCAS) or atherosclerotic vascular disease (MVAS) should be provided upon request by the Régie.

  • Jardiance®

EN219

For the treatment of people with type 2 diabetes whose optimal maximum dose of metformin has been stable for at least one month.
Individuals must also meet the requirements of the recognized indication for the payment of empagliflozin.

  • SynjardyTM

Exception Drug Codes (FR)

Cost

Cost price per molecule

NIHB Canada (Non-Insured Health Benefits)

Drug Benefit List

Patient Exception

Form

Form

Reimbursement
(exception drugs)

Ozempic®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes.
  • When a sulfonylurea is contraindicated, not tolerated or ineffective.
  • Authorization is given for a maximum weekly dose of 1mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

To note:

  • Unlike other GLP-1RA (Victoza and Trulicity), your patients do not need to have tried an iDPP4 or have a BMI > 30 to start treatment.
  • Both doses (0.5mg and 1mg) are reimbursed.


Victoza®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
  • When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
  • The maximum duration of each authorization is 12 months.
  • At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
  • Authorization is given for a maximum daily dose of 1.8 mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

Trulicity®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
  • When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
  • The maximum duration of each authorization is 12 months.
  • At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
  • Authorization is given for a maximum daily dose of 1.5 mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

Dulaglutide
Trulicity®
Liraglutide
Victoza®
Semaglutide
Ozempic®

Strips

Reimbursement and Coding (FR) Update 2017(2017-11-15) (FR)

Dexcom G6®

Provincial Coverage and NIHB Eligibilty Criteria for RAMQ RAMQ Payment Authorization Request Form

Freestyle LibreTM2

Autorisation of payment formulary RAMQ Eligibilty criteria et renewal

Diabetes Screening and Prevention

CANRISK Understanding and preventing type 2 diabetes (DQ)

Evaluation of the Risk of Cardio-Vascular Disease Tool

Patient Questionnaire

Education

A Practical Guide to Diabetes Management (DT2 de novo) Low Blood Sugar-hypoglycemia (DQ) High Blood Sugar-hyperglycemia (DQ) Hypoglycemia / Glucagon

Exam Preparation

Colonoscopy (Insulin Matters Program from Sanofi)

Injection Technic FIT Plus

Insulin Pen Needle Length Site Selection and Rotation Lipohypertrophy (1) Lipohypertrophy (2) Pregnant Women (1) Pregnant Women (2) Older People (1) Older People (2) Kids Teens (1) Teens (2)

Sick-Day Management

Jessie Haggai Tool Urinary Tract Infections and Diabetes (DQ) Yeast Infections and Diabetes (DQ)

Cannabis

Diabetes Canada Position Statement

Travel

Plan Your Trip Letter of Authorization

Driving

Licence (SAAQ) Law and Regulations

Mental Health

Psychologists Quebec Association Quebec Association for Suicide Prevention See Digital Applications Tab

Diabetes Distress Scale (DDS)

La dépression et le diabète DQ) Le stress et le diabète (DQ)

Eye Care

Eye Health and Diabetes – Understanding Diabetic Retinopathy (DQ Retinopathy

Foot Care

AIISPQ (FR) Footcare and diabetes (DQ)

Pregnancy

Gestational Diabetes (DQ) Pregnancy and Type 1 Diabetes (DQ) Pregnancy and Type 2 Diabetes (DQ)

Smoking and Diabetes

J’ARRETE Smoking and Diabetes (DQ)

Ramadan

Diabetes Canada Position Statement Ramadan Calendar Dates

Diabetes Complications

Heart Health and Diabetes – Understanding Cardiovascular Diseases (DQ) Kidney Health and Diabetes – Understanding Diabetic Nephropathy (DQ) Nerve Health and Diabetes – Understanding Diabetic Neuropathy (DQ)

Miscellaneous

Oral Health and Diabetes – Understanding Periodontal Disease (DQ)

Sexuality

Diabète et sexualité féminine (DQ)

Vaccination

Protocole d'immunisation du Québec (PIQ)

- How can I add the app to the home screen of my mobile device?

To get the procedure to add this app, select the button corresponding to your mobile device. Note that the procedure may be slightly different depending on the version of the operating system used.

iPhone / iPad Android

- Do I have to download the application to be able to use it?

No. The application is hosted on a server and accessible via a web browser. The technologies used to develop this web application are the same as those used for the creation of websites. You can add a shortcut to the home screen of your mobile device.


- Does the application also work on my computer?

Yes. Although this application targets mobile devices first it will run properly on most modern web browsers (Mac and PC).


- The application does not seem to work normally.

Make sure Javascript is enabled in your device's web browser (usually enabled by default).


- How can I search for information in the app?

A search engine is located on the homepage below the navigation bar. You can clean the field by typing a new request or by using the to the right of the search button.